The Work We Fund

Funded projects
1,200+
Men's Health Partners
20
Countries
21
"We work closely with our global men's health partners to ensure collaboration, transparency and accountability for every project we fund. We monitor this through report cards which detail what we seek to achieve, key measures and the impact." - Adam Garone, Executive Director, Chief Mo Bro​
Prostate Cancer
"Together with the brightest minds in research, we aim to achieve significant breakthroughs in the hope of beating prostate cancer. Our disruptive funding approach identifies revolutionary ways to accelerate health outcomes by creating strong, global collaborative teams." Dr. Colleen Nelson, Global Scientific Chair.
Men's Health
"One Mo can help change the face of men’s health through the powerful conversations created globally during Movember. Men have the chance to confidently discuss men’s health with people around them, resulting in men taking action early, helping change and save lives." Paul Villanti, Executive Director, Programmes
Mental health and suicide prevention
“We’re alarmed by the increasing number of men who take their own lives around the world. We are working to ensure all men and boys look after their mental health and are comfortable to reach out to others for support when they’re struggling.” Therese Fitzpatrick, Global Mental Health Lead.
Testicular Cancer
“Despite being the 2nd most common cancer in young men, testicular cancer is often a forgotten cancer due to early detection and treatment. Our projects look at underinvested areas such as improving access to healthcare services and treatment options for relapse” Paul Villanti, Executive Director, Programmes.

GAP5 - TIGER Trial in relapsing Germ Cell Tumour

Country
Belgium
Implemented by
The Movember Foundation
Report Card Date
31st July 2016
Reporting period
August 2015 to July 2016
Project Status
In Progress

EUR 1,200,000

Movember Funding to Date

What we seek to achieve

This project supports the European Organisation for Research and Treatments in Cancer (EORTC) to provide sponsorship for the TIGER trial in Europe along with supporting the Australian and New Zealand Urogenital and Prostate Clinical Trials Group (ANZUP) to sponsor contributions in Australia and New Zealand. The TIGER trial is a very large multinational clinical trial investigating which of the two current and commonly used treatments is more effective in preventing death in men who show a relapse of testic

How the project works

Testicular Cancer is a highly treatable disease. In approximately 95% of men, an effective cure can be obtained using first line treatments. However in a small number of men, the disease returns and these men often have a poorer outcome in terms of overall survival and side effects of more toxic treatments. The current standard therapy varies around the world and the TIGER trial aspires to determine which of the current two treatments is more effective. Given that relapse after chemotherapy is quite rare in testicular cancer, a large number of recruiting centres are required to efficiently accrue patients into the study. 420 patients will be recruited worldwide, with 192 of these scheduled to be recruited in European countries and 60 in Australian and New Zealand sites.

The trial strives to guide future clinical practice for the men who are not effectively treated in the first case by chemotherapy. This will guide and shape the treatment of these men to be more appropriate for their circumstance and also potentially reduce unnecessary side effects.

This project has been governed by the Movember Testicular Cancer Research Advisory Committee - a global team of highly regarded experts in the field that have guided and shaped the project.

What we are doing / have done

EORTC will act as European sponsor for the TIGER trial, and ANZUP will act as Australian/New Zealand sponsor.  This means that they will take responsibility for all regulatory, ethics and insurance aspects of delivering the trial in Europe and Australia/New Zealand.  Individual centres in Germany, Belgium, Denmark, Ireland, Switzerland, Spain, Netherlands, France, Italy and United Kingdom will receive per-patient payments to facilitate their involvement in the project.  

To date:

  • EORTC have been contracted to take on sponsorship responsibility of the trial in Europe
  • ANZUP have been contracted to take on sponsorship responsibility of the trial in Australia/New Zealand
  • Each of EORTC and ANZUP have been working closely with the Alliance for Clinical Trials in Oncology (the global sponsor) to complete the appropriate approvals to allow participation of their respective organsiations and countries.
  • An expression of interest and feasibility assessment has been made of clinical centres wishing to participate
  • Regulatory approval of the trial by the Alliance for Clinical Trials in Oncology has been attained and the trial has opened in North America and recruited approximately 16 patients in North America
  • Sites in Europe are working to open for recruitment in 2016.  Belgium has one site open already and several others are poised to open imminently.  

Close this report card

For more information on this project or any of the Movember Funded Projects please contact programs@movember.com

>
Page 1 of 19